Stock search

Ticker or company name

Johnson & Johnson

JNJ · NYSE · Pharmaceuticals

$282,55Down −3,20 (−1,12%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$690 bn
Div. yield
3,1%
Year to date
+38,1%
52 weeks: $193,45$288,11

Ratio score

44/100
Ratio would watch

based on 8 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

2 ✓ · 3 — · 3 ✕ · 2 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM42,922,941,8
Forward P/E23,7—12,4
PEG4,6—3,3
P/S6,95,23,4
EV/EBITDA28,118,324,0
P/FCF33,5—14,0
P/B8,55,78,1

Industry median — across 6 profitable companies in “Pharmaceuticals” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 30 analysts

Buy
21
Hold
9
Sell
0

Beat the EPS forecast in 3 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20262,562,59Up +1,0%
Q2 20262,872,90Up +0,9%
Q1 20262,692,70Up +0,3%
Q4 20252,462,46Down −0,1%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue25,4 bn25,3 bn24,1 bn24,6 bn24,0 bn23,7 bn21,9 bn22,5 bn22,5 bn22,4 bn21,4 bn21,4 bn
EPS0,092,272,142,092,122,294,541,411,111,931,341,67
Margin0,8%21,9%21,8%20,8%21,5%23,3%50,2%15,2%12,0%20,9%15,2%18,9%
FCF6,36 bn7,30 bn1,47 bn5,47 bn8,01 bn2,84 bn3,38 bn5,37 bn6,96 bn4,66 bn2,85 bn6,27 bn

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: purchases $257 688 (1 person), sales $154 m.

NameAmountSharesPrice
forminard elizabeth12 Nov 2026 · sale$3,72 m13 072$284,39
schmid timothy2 Sep 2026 · sale$6,19 m22 527$274,74
schmid timothy2 Sep 2026 · sale$3,04 m11 070$274,74
taubert jennifer l17 Aug 2026 · sale$3,95 m15 000$263,36
duato joaquin13 Aug 2026 · sale$26,7 m102 315$261,00
duato joaquin13 Aug 2026 · sale$5,50 m20 976$262,00
forminard elizabeth6 Aug 2026 · sale$1,68 m6 574$255,93
forminard elizabeth6 Aug 2026 · sale$2,41 m9 344$257,76
duato joaquin5 Aug 2026 · sale$1,69 m6 523$258,74
duato joaquin5 Aug 2026 · sale$10,8 m41 957$258,06
broadhurst vanessa20 Jul 2026 · sale$5,79 m23 054$251,27
wengel kathryn e11 Jun 2026 · sale$2,41 m10 000$241,15
decker robert j27 Feb 2026 · sale$1,01 m4 075$247,87
schmid timothy20 Feb 2026 · sale$324 7631 322$245,66
schmid timothy18 Feb 2026 · sale$2,20 m8 998$244,53

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Pharmaceuticals
Exchange
NYSE
Country
US
IPO date
25 Sep 1944

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
MRKMerck & Co.$144,4638would not consider148,5+4,9%3,6%
LLYLilly (Eli)$1 431,6775would consider49,2+45,5%31,9%
PFEPfizer$28,8644would watch40,8+1,3%6,3%
BMYBristol Myers Squibb$62,9381would consider14,0+4,2%18,5%
ZTSZoetis$84,3975would consider12,4+1,2%26,1%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.